Aromatase Inhibitor News and Research

RSS

Aromatase Inhibitors are drugs that prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy for postmenopausal women who have hormone-dependent breast cancer.

European women soon to have access to new breast cancer drug

European women suffering from breast cancer will soon have access to the breast cancer drug Arimidex after British authorities granted approval for the drug to be used in a wider range of European women with breast cancer.

29 Jun 2005

Designed drug for combined hormone and chemotherapy treatment

The search for new drugs to fight cancer remains at the top of the to do list for pharmaceutical researchers. A recent variation is polymer chemotherapy agents, drugs that have been attached to a "backbone" of long chain molecules.

9 Jun 2005

Study clarifies risk of recurrence for high-risk breast cancer patients

High-risk breast cancer patients do not appear to have a higher risk of relapse than the general breast cancer population during the first two years after diagnosis, unless their cancer has spread to more than 10 axillary lymph nodes, Italian researchers reported at the 2nd ESMO Scientific & Educational Conference (ESEC) in Budapest, Hungary.

6 Jun 2005

Gefitinib (Iressa) could reduce the size of breast cancer tumours

Giving women with early breast cancer a drug called gefitinib (Iressa) before surgery could reduce the size of their tumours, suggests a randomised trial published online today by The Lancet Oncology.

17 May 2005

Zometa reduces bone loss in patients receiving breast cancer treatment

Data presented at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando, Florida, demonstrate that Zometa (zoledronic acid), an intravenous bisphosphonate, was shown to inhibit bone loss in postmenopausal women treated with Femara (letrozole) in the adjuvant breast cancer setting (directly following surgery to prevent cancer recurrence).

16 May 2005

Tamoxifen study counters hopes that drug might protect the heart

Despite previous studies hinting at tamoxifen's potential benefit for breast cancer survivors' heart health, California researchers have found that the breast cancer drug does not decrease survivors' risk of heart attack.

15 May 2005

First North American trial to evaluate the role of an aromatase inhibitor in the prevention of breast cancer

Today, a new clinical trial evaluating a novel approach to breast cancer prevention launched in the United States and Canada. Called the ExCel research study, this is the first North American clinical trial to evaluate the role of an aromatase inhibitor in the prevention of breast cancer.

30 Mar 2005

Call for Anastrozole (Arimidex) to be the new preferred breast cancer treatment option

An international group of breast cancer experts called for the aromatase inhibitor (AI), anastrozole ('Arimidex'), to be considered as the new 'preferred treatment option' for postmenopausal women with early breast cancer.

24 Jan 2005

Study shows women with invasive lobular carcinoma may not need chemotherapy before surgery

Women with a rare type of advanced breast cancer who do not benefit from primary (pre-surgical) chemotherapy still have been found to do better in the long run than patients with a more common advanced breast cancer who do respond to chemotherapy.

3 Jan 2005

Landmark studies that may change the treatment standards for breast cancer

The 27th Annual San Antonio Breast Cancer Symposium that took place December 8-11 included the presentation of several landmark studies that may change the treatment standards for breast cancer.

14 Dec 2004

Presentation of the most recent and advanced work in the rapidly progressing field of fertility preservation

Each year approximately 50,000 women under the age of 40 are diagnosed with breast cancer. Treatments vary but most involve the administration of chemotherapeutic agents or radiation which can disrupt ovarian function or damage a patient’s eggs.

18 Oct 2004

More women are surviving advanced breast cancer

Writing in the Journal of Clinical Oncology, (Vol. 22, No. 16: 3302-3308), doctors from 3 French hospitals reported on 724 women whose first diagnosis was breast cancer that had spread to other parts of the body (stage 4). It is rare for women to be diagnosed with such late stage disease.

27 Aug 2004

New early breast cancer treatment significantly reduces the risk of cancer returning

Marking the first major treatment advance since tamoxifen's introduction over 25 years ago, Canada's leading oncologists and breast cancer patient support and advocacy groups gathered to applaud a new era in treatment for early breast cancer.

15 Jul 2004

Strategic analysis of the breast cancer therapeutics pipeline

Strategic partnerships between the pharmaceuticals industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market.

15 Jul 2004

New treatment significantly improves long-term outlook for breast cancer survivors

An updated analysis from an international clinical trial of the drug letrozole was presented on June 8, 2004 at the American Society of Clinical Oncology annual meeting in New Orleans.

11 Jun 2004

Serum estrogen receptor modulator's (SERM's) may help reduce postmenopausal breast cancer risk

Newest research findings were presented on the possible benefits they may provide for postmenopausal breast cancer risk reduction. SERMs are a class of drugs that can block the cell's ability to use estrogen to stimulate the development of breast cancer.

7 Jun 2004

Women who regularly take aspirin at lower risk of breast cancer

Women who regularly take aspirin seem to be at lower risk of the most common type of breast cancer than those who do not take aspirin, report researchers from Columbia University's Mailman School of Public Health and College of Physicians & Surgeons, Weill Cornell Medical College , and New York-Presbyterian Hospital.

31 May 2004

Pfizer breast cancer drug looks to be best in field

A breast cancer drug made by Pfizer Inc. increased survival rates by 63 percent compared with the standard therapy tamoxifen, researchers said on Wednesday. The clinical trial strengthens the case for administering the newer drug, exemestane, as a first option. A study published last week showed that women recovering from breast cancer lowered their chance of developing another tumor by 32 percent if they switched to exemestane after two or three years of tamoxifen treatment.

22 Mar 2004